Retinal Hyperspectral Imaging in Neurodegenerative Diseases

Inclusion Criteria: 1. Aged over 30 years. 2. Have dementia or a neurodegenerative disease such as Alzheimer's disease, Parkinson's disease, Lewy body dementia, Niemann-Pick type 2 or vascular dementia (age-matched and sex-matched controls will also be recruited). 3. With the exception of participants with Parkinson's disease and Lewy body disease, for whom clinical examination by a neurologist is sufficient to establish a clinical diagnosis of probable dementia with Lewy Body or probable Parkinson disease dementia, all participants must have previously undergone at least of one of the following tests to help to confirm a clinical diagnosis of dementia or neurodegenerative disease: genetic tests, blood biomarker tests (amyloid, tau, neurofilament light), a brain amyloid beta PET scan, or cerebrospinal fluid tests. 4. Have a minimum best corrected visual acuity level of 6/60 in both eyes and no major eye problems, such as advanced age-related macular degeneration, advanced glaucoma, or greater than moderate non-proliferative diabetic retinopathy. 5. Be willing to participate in the study and attend the Centre for Eye Research Australia. 6. Be accompanied by a friend or family member. Exclusion Criteria: 1. Inability to provide informed consent 2. Ocular conditions preventing adequate retinal imaging (e.g., dense cataract, severe corneal opacity, vitreous haemorrhage) 3. Known contraindication to pharmacological pupil dilation 4. Any condition that, in the investigator's opinion, would compromise participant safety or image quality